Pain Therapeutics (NASDAQ:PTIE) Trading Up 11.7%

Pain Therapeutics, Inc. (NASDAQ:PTIE) was up 11.7% during mid-day trading on Friday . The company traded as high as $1.24 and last traded at $1.24. Approximately 0 shares traded hands during mid-day trading, a decline of 100% from the average daily volume of 249,125 shares. The stock had previously closed at $1.11.

Pain Therapeutics (NASDAQ:PTIE) last posted its quarterly earnings results on Monday, March 25th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.57.

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. grew its position in Pain Therapeutics by 11.4% in the fourth quarter. BlackRock Inc. now owns 226,066 shares of the biopharmaceutical company’s stock worth $193,000 after acquiring an additional 23,204 shares during the period. Geode Capital Management LLC grew its position in Pain Therapeutics by 75.0% in the fourth quarter. Geode Capital Management LLC now owns 66,068 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 28,314 shares during the period. Finally, Vanguard Group Inc grew its position in Pain Therapeutics by 20.7% in the third quarter. Vanguard Group Inc now owns 218,850 shares of the biopharmaceutical company’s stock worth $221,000 after acquiring an additional 37,466 shares during the period. Institutional investors and hedge funds own 17.40% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2019/06/14/pain-therapeutics-nasdaqptie-trading-up-11-7.html.

About Pain Therapeutics (NASDAQ:PTIE)

Pain Therapeutics, Inc develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease.

Recommended Story: Balanced Fund

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.